Gaining Critical Characterization Insights for Development of CAR-T Therapies for Solid Tumors

Download the eBook featuring an Expert Roundtable discussion with leading CAR-T scientists as they share their valuable insights on the current status, existing challenges, and future advancements and state-of-the-art cell analysis technologies assisting CAR T cell therapy discovery and development as it seeks to advance beyond haematological malignancies and into the solid tumor space.

Experts from two of the foremost cell & gene therapy biotechs seeking to drive this transition, plus a leading academic and analytics tool provider, assemble to discuss progress to date and next steps in this vital endeavor.

• Dr Sadik Kassim, Executive Director, Kite Pharma, A Gilead Company. With a CV boasting the likes of Johnson & Johnson, the NIH, Novartis and Mustang Bio, Dr Sadik Kassim brings a wealth of experience and expertise spanning rare diseases, AAV-based gene therapy, immunotherapy, oncology, CAR-T cell therapies and CMC to his new role at Kite Pharma.
• Tamara J. Laskowski, PhD, Senior Research Scientist - Immunotherapy, Allison Group Department of Immunology, MD Anderson Cancer Center. Having originally joined Dr. Laurence J.N. Cooper’s laboratory as a fellow, where her work focused on engineering stem cells with the goal of generating off-the-shelf NK and T-cell immunotherapies for targeting solid tumor malignancies, Dr Tamara Laskowski recently transitioned to Dr. James Allison’s Immunotherapy Platform at MD Anderson Cancer Center. In her new role Dr. Laskowski’s work primarily involves immune-monitoring of patients undergoing clinical trials in Immunotherapy and development of novel immunoassays.
• Dr Janani Krishnamurthy, Senior Scientist, Atara Biotherapeutics. An expert in the fields of immunology, adoptive immunotherapy and neuroimmunology, Dr Janani Krishnamurthy enjoyed stints at MD Anderson, bluebird bio and TCR2 Therapeutics before taking on her current role leading EBV+ve CAR T cell pre-clinical initiatives for targeting solid tumours at Atara Biotherapeutics.
• John O’Rourke, Head Of Product Development, Cell Analytics, Sartorius. John O’Rourke completed his PhD in Biochemistry from The Ohio State University where he studied cancer biology and gene regulation. During his postdoctoral training at Nationwide’s Children’s Research Institute in Columbus, Ohio and the University of New Mexico, he continued his studies in cancer biology along with the development of viral and nanoparticle-based therapeutics.

Learn more about information-rich solutions for CAR-T research from Sartorius at www.sartorius.com/car-t-research.